Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.70 |
| ▸ | CA2 | P00918 | 6/20 | 0.70 |
| ▸ | CA12 | O43570 | 5/20 | 0.70 |
| ▸ | CA9 | Q16790 | 5/20 | 0.70 |
| ▸ | CA7 | P43166 | 4/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.70 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.65 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496051 | 0.86 | CA12 (0.70) | CA1CA2CA12CA9CA7 | |
| SCHEMBL1179501 | 0.85 | CYP4F2 (0.53) | CA1CA2CA12CA9CA7 | |
| SCHEMBL2406530 | 0.84 | CYP4F2 (0.67) | CA1CA2CA12CA9CA7 | |
| SCHEMBL11225504 | 0.84 | CYP4F2 (0.67) | CYP4F2CYP4A11KMT2ATSHRALDH1A1 | |
| SCHEMBL10449048 | 0.84 | CA12 (0.77) | CA1CA2CA12CA9CA7 | |
| SCHEMBL320406 | 0.83 | CYP4F2 (0.79) | CA1CA2CA12CA9CA7 | |
| SCHEMBL550228 | 0.82 | CA12 (0.74) | CA1CA2CA12CA9CA7 | |
| SCHEMBL29457603 | 0.82 | CA12 (1.00) | CA1CA2CA12CA9CA7 | |
| SCHEMBL39259 | 0.82 | CA12 (1.00) | CA1CA2CA12CA9CA7 | |
| SCHEMBL194508 | 0.81 | CYP4F2 (0.63) | CA1CA2CA12CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| EP-4048399-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021080013-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021080013-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-04-29 | — | — | WO | disclosed |
| EP-3212647-B1 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG A ST CO LTD (KR) | 2019-04-03 | — | — | EP | disclosed |
| EP-3212647-B1 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG A ST CO LTD (KR) | 2019-04-03 | — | — | EP | disclosed |
| EP-2882749-B1 | 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-04 | — | — | EP | disclosed |
| EP-2882749-B1 | 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-04 | — | — | EP | disclosed |
| US-9926276-B2 | Substituted benzamides with activity towards EP4 receptors | DRACONIS PHARMA, S.L. (ES) | 2018-03-27 | — | — | US | disclosed |
| US-9834550-B2 | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-2882749-A1 | 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES | Boehringer Ingelheim International GmbH (DE) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014122267-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | DRACONIS PHARMA, S.L. (ES) | 2014-08-14 | — | — | WO | disclosed |
| EP-2765128-A1 | Substituted benzamides with activity towards EP4 receptors | Almirall, S.A. (ES) | 2014-08-13 | — | — | EP | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| WO-2014019979-A1 | 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | PDE12, PDE2A, PDE3A | CA1 1649/4885CA2 592/4885CA12 1661/4885 |
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | CA1 2729/4885CA2 710/4885CA12 4815/4885 |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | PDE12, PDE2A, PDE3A | CA1 1649/4885CA2 592/4885CA12 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.